María José Lechuga

3.1k total citations · 2 hit papers
25 papers, 2.3k citations indexed

About

María José Lechuga is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, María José Lechuga has authored 25 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 5 papers in Surgery. Recurrent topics in María José Lechuga's work include Gastric Cancer Management and Outcomes (10 papers), Renal cell carcinoma treatment (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). María José Lechuga is often cited by papers focused on Gastric Cancer Management and Outcomes (10 papers), Renal cell carcinoma treatment (7 papers) and Colorectal Cancer Treatments and Studies (7 papers). María José Lechuga collaborates with scholars based in United States, Italy and France. María José Lechuga's co-authors include Éric Raymond, Ann‐Lii Cheng, Yoon‐Koo Kang, Silvana Lanzalone, Paola Gerletti, Craig Eagle, Rebecca B. Rosenstein, Shukui Qin, Julius Špičák and Miroslav Zavoral and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

María José Lechuga

24 papers receiving 2.2k citations

Hit Papers

Celecoxib for the Prevention of Colorectal Adenomatous Po... 2006 2026 2012 2019 2006 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Celecoxib for the Prevention of Colorectal Adenomatous Polyps
    2006 751 citations Nadir Arber, Craig Eagle et al. New England Journal of Medicine profile →
  2. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
    2013 586 citations Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
María José Lechuga United States 14 754 731 672 515 510 25 2.3k
Christopher A. Carter United States 12 804 1.1× 512 0.7× 497 0.7× 415 0.8× 948 1.9× 15 2.4k
Wataru Ichikawa Japan 28 1.5k 2.0× 131 0.2× 1.2k 1.8× 345 0.7× 699 1.4× 136 2.7k
E. Brendel Germany 21 818 1.1× 289 0.4× 558 0.8× 269 0.5× 891 1.7× 53 2.1k
Henry Q. Xiong United States 18 2.8k 3.8× 924 1.3× 1.3k 1.9× 271 0.5× 1.2k 2.4× 39 4.3k
Liwei Wang China 32 2.0k 2.7× 182 0.2× 778 1.2× 494 1.0× 1.9k 3.7× 112 3.9k
Emily G. Barr Fritcher United States 22 951 1.3× 309 0.4× 1.0k 1.5× 189 0.4× 357 0.7× 44 2.3k
Linda Janisch United States 23 2.1k 2.8× 227 0.3× 738 1.1× 245 0.5× 1.7k 3.4× 68 3.6k
Erika Martinelli Italy 33 2.1k 2.8× 981 1.3× 1.2k 1.8× 672 1.3× 1.8k 3.5× 109 4.4k
Shukui Qin China 25 1.9k 2.5× 544 0.7× 1.5k 2.2× 461 0.9× 538 1.1× 95 3.1k
Paula K. Locker United States 13 2.5k 3.3× 868 1.2× 762 1.1× 334 0.6× 791 1.6× 16 3.1k

Countries citing papers authored by María José Lechuga

Since Specialization
Citations

This map shows the geographic impact of María José Lechuga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María José Lechuga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María José Lechuga more than expected).

Fields of papers citing papers by María José Lechuga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María José Lechuga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María José Lechuga. The network helps show where María José Lechuga may publish in the future.

Co-authorship network of co-authors of María José Lechuga

This figure shows the co-authorship network connecting the top 25 collaborators of María José Lechuga. A scholar is included among the top collaborators of María José Lechuga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María José Lechuga. María José Lechuga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rini, Brian I., Thomas E. Hutson, Robert A. Figlin, et al.. (2018). Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clinical Genitourinary Cancer. 16(4). 298–304. 42 indexed citations
2.
George, Daniel J., Jean-François Martini, Michael Staehler, et al.. (2018). Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clinical Cancer Research. 24(7). 1554–1561. 32 indexed citations
3.
Kudo, Masatoshi, Yoon‐Koo Kang, Joong‐Won Park, et al.. (2017). Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study. Liver Cancer. 7(2). 148–164. 7 indexed citations
4.
Reichardt, Peter, George D. Demetri, Hans Gelderblom, et al.. (2016). Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 16(1). 22–22. 53 indexed citations
5.
Reichardt, Peter, Yoon‐Koo Kang, Piotr Rutkowski, et al.. (2015). Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment‐use trial of sunitinib. Cancer. 121(9). 1405–1413. 85 indexed citations
6.
Hecht, J. Randolph, Edith Mitchell, Takayuki Yoshino, et al.. (2015). 5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study. Cancer Management and Research. 7. 165–165. 9 indexed citations
7.
Carrato, Alfredo, Anna Świeboda-Sadlej, Robert Lim, et al.. (2013). Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. Journal of Clinical Oncology. 31(10). 1341–1347. 110 indexed citations
8.
Cheng, Ann‐Lii, Yoon‐Koo Kang, Deng‐Yn Lin, et al.. (2013). Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 31(32). 4067–4075. 586 indexed citations breakdown →
9.
Yoshino, Takayuki, Kentaro Yamazaki, Tetsuya Hamaguchi, et al.. (2012). Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.. PubMed. 32(3). 973–9. 6 indexed citations
10.
Cutsem, Eric Van, Feng Gao, James A. Williams, et al.. (2011). ASSOCIATIONS BETWEEN GERMLINE GENOTYPE AND EFFICACY AND SAFETY OUTCOMES IN A PHASE III STUDY OF SUNITINIB AND FOLFIRI IN METASTATIC COLORECTAL CANCER (MCRC). Annals of Oncology. 22. 1 indexed citations
11.
Harmon, Charles S., Samuel E. DePrimo, Éric Raymond, et al.. (2011). Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. Journal of Translational Medicine. 9(1). 120–120. 19 indexed citations
12.
Arber, Nadir, Julius Špičák, I Rácz, et al.. (2011). Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial. The American Journal of Gastroenterology. 106(6). 1135–1146. 59 indexed citations
13.
Faivre, Sandrine, Magaly Zappa, Valérie Vilgrain, et al.. (2011). Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib. Clinical Cancer Research. 17(13). 4504–4512. 72 indexed citations
14.
Bang, Yung‐Jue, Yoon‐Koo Kang, Won Ki Kang, et al.. (2010). Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investigational New Drugs. 29(6). 1449–1458. 153 indexed citations
15.
Faivre, Sandrine, Éric Raymond, Éveline Boucher, et al.. (2009). Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. The Lancet Oncology. 10(8). 794–800. 219 indexed citations
16.
Arber, Nadir, Julius Špičák, I Rácz, et al.. (2008). Chemopreventive Effectiveness of Celecoxib Two Years After Cessation of Treatment. Gastroenterology. 135(1). 295–296. 1 indexed citations
17.
Reck, Martin, Norbert Frickhofen, U. Gatzemeier, et al.. (2007). P3-134: Sunitinib in combination with gemcitabine plus cisplatin for advanced non–small cell lung cancer (NSCLC): preliminary results from a phase I dose escalation study. Journal of Thoracic Oncology. 2(8). S736–S736. 1 indexed citations
18.
Arber, Nadir, Craig Eagle, Julius Špičák, et al.. (2006). Celecoxib for the Prevention of Colorectal Adenomatous Polyps. New England Journal of Medicine. 355(9). 885–895. 751 indexed citations breakdown →
19.
Merlini, Giampaolo, Ernesto Anesi, Pietro Garini, et al.. (1999). Treatment of AL Amyloidosis with 4′-Iodo-4′-Deoxydoxorubicin: An Update. Blood. 93(3). 1112–1113. 30 indexed citations
20.
Escobedo, Agustín, et al.. (1992). Treatment of pre-menopausal advanced breast cancer with goserelin—a long-acting luteinizing hormone releasing hormone agonist. Anti-Cancer Drugs. 3(1). 3–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher A. Carter Breakdown of academic impact, for papers by Wataru Ichikawa Breakdown of academic impact, for papers by E. Brendel Breakdown of academic impact, for papers by Henry Q. Xiong Breakdown of academic impact, for papers by Liwei Wang Breakdown of academic impact, for papers by Emily G. Barr Fritcher Breakdown of academic impact, for papers by Linda Janisch Breakdown of academic impact, for papers by Erika Martinelli Breakdown of academic impact, for papers by Shukui Qin Breakdown of academic impact, for papers by Paula K. Locker
Rankless by CCL
2026